University of British Columbia
Enhancement of the GluN2B subtype of n-methyl-d-aspartate glutamate receptor for memory improvement
Abstract
dc:descriptionThe N-methyl-D-aspartate glutamate receptors (NMDAR) containing the GluN2B subunit are important for synaptic plasticity and various types of learning and memory. It has been shown that disrupting the function of GluN2B using genetic knockout or pharmacological inhibitors impaired activity-dependent synaptic plasticity and memory performances in rodents, whereas genetic enhancement of GluN2B expression in cortical neurons of rodents enhanced synaptic plasticity and learning. Based on these findings, we hypothesize that pharmacological enhancement of the GluN2B-NMDAR function will facilitate NMDAR-dependent synaptic plasticity and hence learning and memory in wildtype rats. To test our hypothesis, we identified GluN2B-NMDAR-specific positive allosteric modulators using computer-assisted virtual high throughput screening combined with in vitro drug screening assays measuring their NMDAR modulatory activities. We then optimized the potency and GluN2B-selectivity of our hit compounds using structural-based approaches, which led to the development of lead modulators with ~50 nanomolar potency on GluN2B-NMDAR and over 50-fold selectivity against GluN2A and other NMDAR subtypes. Using a combination of electrophysiology and molecular biology techniques, we further characterized the pharmacological properties and the binding site of the lead compounds. Following that, we conducted in vivo functional studies using our blood-brain barrier penetrant lead compound 175. We found that systemic administration of 175 facilitated bidirectional synaptic plasticity in the dorsal hippocampus of anesthetized rats. We next provided initial evidence that 175 administrations facilitated learning in rats using a novel object recognition test. Overall, our studies developed the first potent and selective GluN2B-NMDAR positive allosteric modulator and suggested the possibility for the wide-ranging in vivo application of the drug as a research tool and a treatment for cognitive deficits in neurological diseases.
Degree
thesis:*- Name thesis:degree_name
- Doctor of Philosophy - PhD
- Level thesis:degree_level
- doctoral
- Discipline thesis:degree_discipline
- Neuroscience
- Grantor dc:publisher
- University of British Columbia
- Year dc:date
- 2022
Author and committee
dc:creator, dc:contributor.*- Author dc:creator
-
- Ge, Yang
- Contributors dc:contributor
-
- Wang, Yu Tian
Rights
dc:rights- Statement dc:rights
-
- Attribution-NonCommercial-NoDerivatives 4.0 International
- Language dc:language
- eng
Identifiers
dc:identifier.*- Handle dc:identifier
- http://hdl.handle.net/2429/83602